JPH1121247A - Skin activator and allergy inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a skin activator excellent in synthetic activities of biological hyaluronic acid and inhibiting activities of hyaluronidase, and further to obtain an allergy inhibitor having excellent activities for inhibiting release of histamine. SOLUTION: This skin activator and allergy inhibitor contain fucoidan extracted from one or more kinds of a seaweed belonging to the genus Analipus, Nemacystis, Ceratophyllum, Ecklonia, Lessonia, Macrocystis, Fucus, Ascophyllum and Durvillea.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to an extremely safe skin activator and allergy inhibitor comprising a polysaccharide fucoidan obtained from a specific seaweed species as an active ingredient.

[0002]

2. Description of the Related Art Seaweed contains carrageenan, alginic acid, fucoidan, laminarin and the like as polysaccharides different from other plants. Among them, carrageenan and alginic acid are widely used as viscous substances in the fields of foods, cosmetics, pharmaceuticals and the like as highly viscous substances. However, fucoidan is not yet widely used.

[0003] Conventionally, in the field of cosmetics, attention has been paid to the viscosity and moisturizing properties of fucoidan obtained from kelp, alame, wakame, mekabu, etc.
Applications for improving the feeling of use, such as imparting a moist feeling and removing excess sebum, have been studied (Japanese Patent Application Laid-Open No. 1-31).
No. 707, Japanese Patent Publication No. 7-14850, JP-A-1-305
No. 011). However, all of these focus on the physical properties of fucoidan. recently,
Anti-inflammatory effect of inhibiting the enzyme phospholipase A ₂ which promotes arachidonic acid release from a phospholipid (JP 8-921
No. 03), blood coagulation action, cholesterol deposition prevention action, antitumor action (Seaweed Chemistry, 1993, Asakura Shoten), anticancer action (18th Carbohydrate Symposium Abstracts, 1996), and other physiological actions of fucoidan Although knowledge has begun to emerge, little is known about its physiological and biochemical effects on skin and allergies.

[0004] It is an object of the present invention to provide an excellent skin activator having a biological hyaluronic acid synthesizing action and a hyaluronidase inhibitory action and an excellent allergy inhibitor having a histamine release inhibiting action.

[0005]

Means for Solving the Problems and Embodiments of the Invention In order to solve the above-mentioned problems, the present inventors have studied the action of promoting the synthesis of hyaluronic acid in rat epidermal cells using various natural products, especially plant extracts. JP-A-6-9422, JP-A-8-1
Japanese Patent Application No. 988741, Japanese Patent Application No. 7-9065, Japanese Patent Application No.
No. 341705), as a result of intensive screening using hyaluronidase activity inhibitory activity (Japanese Patent Application No. 8-158110) and histamine release inhibitory activity of mast cells as indexes.
These particularly strong effects were found in extracts of seaweeds belonging to specific seaweeds, namely, the brown algae Matsumo genus, Mozuku genus, Bombyx genus, Lessonia genus, Macrocystis genus, Hibamata genus, Ascophyllum genus, and Darbilia genus.

[0006] Further, as a result of examining the active ingredient in the extract in which these effects were recognized, fucoidan was found as one of the active ingredients from any of the seaweeds, and the present invention was completed.

[0007] Fucoidan is a kind of sulfated polysaccharide extracted from brown algae, and is basically composed mainly of 1,2-bonds of L-fucose-4-sulfate. 4-
In addition to the presence of a bond, there are many cases where the constituent sugars include uronic acids such as glucuronic acid and neutral sugars such as galactose, xylose, rhamnose and mannose, and the composition differs depending on the species of seaweed. For this reason, it was speculated that different sugar chains have different physiological activities.However, it is extracted from seaweed, especially brown algae kelp and honda straw, which are conventionally considered to be good for skin by enhancing moisturizing properties. Fucoidan thus obtained has weak effects, and the effect of the present invention was specific to fucoidan obtained from the above specific seaweed. In addition, such an effect was not recognized in other seaweed polysaccharides such as carrageenan and alginic acid.

[0008] That is, the skin activator and allergy inhibitor of the present invention are extracted from seaweeds belonging to the brown alga Matsumo, Mozuku, Kajime, Lessonia, Macrocystis, Hibamata, Ascophyllum and Darbilia. Characterized in that it contains fucoidan as an active ingredient.

[0009] The mechanism by which fucoidan of the present invention exerts an excellent skin activating action is improved by improving the ability of epidermal cells to synthesize hyaluronic acid, which has been reduced due to aging, and by suppressing the degradation of hyaluronic acid in skin cells. It is presumed that it maintains the level of hyaluronic acid in the skin, suppresses a decrease in the moisturizing property, flexibility and elasticity of the skin, and exhibits a remarkable antiaging effect on the skin.

On the other hand, histamine is known as an in vivo mediator causing various allergic symptoms, and is mainly released from mast cells and basophils by degranulation. Recently, studies suggesting that hyaluronidase is involved in histamine release from mast cells (inflammation,
Vol. 4, pp 437, 1984; Chem. Pha
rm. Bull. , Vol. 33, pp642, 198
5; Chem. Pharm. Bull. , Vol. 3
3, pp 5079, 1985), screening of natural products having an anti-allergic effect has been actively carried out using hyaluronidase inhibitory activity as an index. Then, when these actions were confirmed, fucoidan of the present invention was found to have a strong hyaluronidase inhibitory action and a histamine release inhibitory action, and thus the fucoidan of the present invention is extremely effective as an allergy inhibitor.

Hereinafter, the contents of the present invention will be described in detail.
As a seaweed for extracting fucoidan used in the present invention, for example, a brown alga, Matsumo genus, contains a Japanese peach (Anali).
pus japonicus), Mozuku (Nemacysis decipiens) for the genus Mozuku, Ecklonia cava (Ecklonia cava) for the genus Kazuki, Ecklonia maxim (Ecklonia maxim)
a), Lessonia nigrescens for Lessonia sp., Giant kelp for Macrocystis sp.
tis pyrifera), in the genus Hibamata, Hibamata (Fucus evanescens), Fucus vesiculosus (Fucus vesiculosus),
In the genus Ascophyllum, Ascophyllum nodsum (A
scophyllum nodosum, and of the genus Darvila, Durville antarctica (Durville)
ea antarctica) and the like.

[0012] Particularly, as a seaweed for extracting fucoidan used as a skin activator from the viewpoint of a hyaluronic acid synthesis promoting effect, preferably, Durville ant is used.
arctica, Ecklonia maxima, F
ucus vesiculosus, hibamata is good.
Further, as a seaweed for extracting fucoidan used as an allergy inhibitor from the viewpoint of a hyaluronidase inhibitory effect and a histamine release inhibitory effect, preferably Ec is used.
klonia maxima, swordfish, Fucus v
esiculosus, Durville anta
rctica, Lessonia nigrescen
s is good.

The above-mentioned seaweed fucoidan may be used as a crude extract or may be used by separating and purifying it from the crude extract.

The method for obtaining the substance fucoidan of the present invention from seaweed is not particularly limited, and a usual extraction method is employed. The crude extract can be obtained by extracting a shred of all seaweed using a solvent obtained by using water, an acid or a hydrophilic organic solvent alone or in combination. In this case, as the organic solvent, methanol, ethanol, alcohols such as butanol, esters such as ethyl acetate,
Examples thereof include ketones such as acetone, formaldehyde, dimethyl sulfoxide and the like.

The extraction conditions for the crude extract are not particularly limited, but are preferably in the range of 5 to 100 ° C.
It is preferable to carry out with stirring for 1 to 24 hours.

As a method for separating and purifying fucoidan from the crude extract, for example, a method for separating and purifying fucoidan such as cetylpyridinium chloride.
There is a method in which fucoidan is precipitated by adding a quaternary ammonium salt and washed with an alcohol solution, or a method using chromatography using an anion exchange resin such as DEAE cellulose.

The fucoidan solution extracted from the seaweed may be used as it is, or may be used as a dilute solution or as a concentrated extract, or may be prepared as a dry powder by freeze-drying or the like, or may be prepared in a paste form.

The skin activator and allergy inhibitor containing the seaweed extract of the present invention can be used in the form of an external preparation for skin. Raw materials used in the agent, for example, surfactants, oils, alcohols, humectants, thickeners, preservatives,
An antioxidant, a chelating agent, a pH adjuster, a fragrance, a pigment, an ultraviolet absorbing / scattering agent, vitamins, amino acids, water and the like can be added.

Specifically, as the surfactant, lipophilic glycerin monostearate, self-emulsifying glycerin monostearate, polyglycerin monostearate, sorbitan monooleate, polyethylene glycol monostearate are used as nonionic surfactants. Ester type such as polyoxyethylene sorbitan monooleate, ether ester type such as polyoxyethylene hydrogenated castor oil, polyoxyethylene cetyl ether, polyoxyethylenated sterol, polyoxyethylenated lanolin, polyoxyethylenated An ether type such as beeswax can be exemplified.

Examples of the anionic surfactant include a carboxylate type, a sulfonate type, a sulfate ester type and a phosphate ester type. Examples of the carboxylic acid type include higher fatty acid salts such as sodium stearate, potassium palmitate and triethanolamine palmitate, sodium N-lauroyl-N-methylglycine, N-myristyl-N
Examples thereof include N-acyl amino acid salts such as potassium-methyl-β-alanine and triethanolamine N-palmitylglutamate, and alkyl ether carboxylate salts such as potassium lauryl ether carboxylate. Examples of the sulfonate type include sodium cetyl sulfonate, examples of the sulfate type include sodium lauryl ether sulfate, and examples of the phosphate type include sodium lauryl phosphate and sodium polyoxyethylene lauryl phosphate.

Examples of the cationic surfactant include stearyldimethylbenzylammonium chloride and stearyltrimethylammonium chloride.

Examples of the amphoteric surfactant include an amphoteric surfactant such as an alkylaminoethylglycine chloride solution and lecithin.

Examples of oils include vegetable oils such as castor oil, olive oil, cacao oil, camellia oil, coconut oil, wood wax, jojoba oil, grape seed oil, avocado oil, animal oils such as mink oil, egg yolk oil, and honey. Waxes such as wax, whale wax, lanolin, carnauba wax, candelilla wax, liquid paraffin, squalane, microcrystalline wax, ceresin wax, paraffin wax, hydrocarbons such as petrolatum, lauric acid, myristic acid, stearic acid, oleic acid Natural and synthetic fatty acids such as isostearic acid and behenic acid, natural and synthetic higher alcohols such as cetanol, stearyl alcohol, hexyldecanol, octyldodecanol, lauryl alcohol, isopropyl myristate, isopropyl palmitate, isopropyl adipate, Risuchin octyldodecyl, octyldodecyl oleate, can be exemplified cholesterol oleate esters such like.

Examples of the humectant include polyhydric alcohols such as glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, polyglycerin, polyethylene glycol and dipropylene glycol, amino acid derivatives such as trimethylglycine, sodium lactate and pyrrolidone carboxylic acid. Examples include NMF components such as sodium acid and amino acids, and water-soluble polymer substances such as hyaluronic acid, collagen, mucopolysaccharide, and chondroitin sulfate.

Examples of the thickener include carrageenan, sodium alginate, xanthan gum, aluminum silicate,
Examples include natural polymer substances such as quince seed extract, tragacanth gum, and starch, and semi-synthetic polymer substances such as methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, soluble starch, and cationized cellulose.

Preservatives include benzoate, salicylate, sorbate, dehydroacetate, paraoxybenzoate, 2,4,4'-trichloro-2'-hydroxydiphenyl ether, 3,4,4'- Trichlorocarbanilide, benzalkonium chloride, hinokitiol,
Resorcinol, ethanol and the like can be exemplified.

As antioxidants, dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, ascorbic acid, etc., and as chelating agents, disodium edetate, ethylenediaminetetraacetate, pyrophosphate, hexametaphosphate, citrate Acid, tartaric acid, gluconic acid, etc., as a pH adjuster, sodium hydroxide,
Examples thereof include triethanolamine, citric acid, sodium citrate, boric acid, borax, potassium hydrogen phosphate and the like.

Examples of the ultraviolet absorbing / scattering agent include 2-hydroxy-4-methoxybenzophenone, octyldimethyl paraaminobenzoate, ethylhexyl paramethoxycinnamate, titanium oxide, kaolin, talc and the like.

The vitamins include vitamin A, vitamin B group, vitamin C, vitamin D, vitamin E, vitamin F, vitamin K, vitamin P, vitamin U, carnitine, ferulic acid, γ-oryzanol, α-lipoic acid, Orotic acids and their derivatives can be exemplified.

The amino acids include glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, tryptophan,
Examples thereof include cystine, cysteine, methionine, proline, hydroxyproline, aspartic acid, asparagine, glutamic acid, glutamine, arginine, histidine, lysine, and derivatives thereof.

The dosage form of the skin activator and allergy inhibitor of the present invention can be tablets, capsules, powders, oral liquids, fine powders and other internal medicines, and troches, candy, gums and other foods. Also, it can be used for the outer skin of liniment, spray, lotion, jelly, ointment and the like.

In these preparations, fucoidan, which is an essential component, can be added at any concentration.
0% (% by weight, hereinafter the same), preferably 0.1 to 10%
It is good to mix.

The dose of fucoidan of the present invention can be 0.02 to 1000 mg per adult per day.

The formulation examples of the preparation of the present invention are shown below. (1) Skin cream Fucoidan of the present invention 0.1 to 10%, oil content 20 to 70
%, Surfactant 2 to 7%, humectant 1 to 10%, purified water balance, trace amount of preservative, trace amount of fragrance. (2) Emulsion 0.1 to 10% of fucoidan of the present invention, oil content of 10 to 40
%, Alcohols 0 to 15%, surfactants 1 to 5%, humectants 1 to 10%, thickeners 0 to 2%, purified water balance, trace amounts of preservatives, trace amounts of perfume. (3) Lotion, essence 0.1 to 10% of fucoidan of the present invention, alcohols 5
20%, surfactant 0-2%, humectant 2-8%, thickener 0-2%, antioxidant 0-0.5%, chelating agent 0
0.1%, pH adjuster 0-0.2%, purified water balance,
A composition containing a trace amount of a preservative, a trace amount of a pigment, and a trace amount of a fragrance. (4) Packing agent 0.1 to 10% of fucoidan of the present invention, alcohols 2 to 2
A composition containing 10%, humectant 2 to 10%, inorganic powder 0 to 20%, film-forming agent 10 to 20%, purified water balance, a small amount of preservative, and a small amount of fragrance. (5) Ame fucoidan of the present invention 0.1 to 10%, sugar 10 to 70
%, Syrup 20 to 50%, organic acid 0 to 20%, palatinose 0 to 70%, aspartame 0 to 70%, xylitol 0 to 70%, purified water balance, and a small amount of flavor. (6) Lozenge fucoidan 0.1 to 10% of the present invention, glucose 0 to 70
%, Palatinose 0-85%, Aspartame 0-85
%, Xylitol 0-85%, gum arabic 3-20
%, Talc 0-15%, magnesium stearate 0
Composition containing 5%, purified water balance, trace amounts of fragrance.

[0035]

Next, the present invention will be described in detail with reference to Test Examples and Examples, but the present invention is not limited to the following Examples.

[Production Example] Extraction and Purification of Fucoidan Extraction and purification of fucoidan from seaweed were carried out by the method of Mizui et al. (KitastoArch. Exp. Med., V
ol. 58, pp59, 1985). Ecklonia maxim
An example performed for a) is shown below.

Eglonia maxima 180 g of dried algal cells were pulverized using a mixer, added with a 20-fold amount of distilled water, and extracted at room temperature for 3 hours with stirring. The extract was filtered and lyophilized to obtain 30.7 g of a water extract.

20 g of the water extract was dissolved in 2 L of distilled water (1
% Solution) and distilled water, and the dialysis solution was freeze-dried to obtain 2.9 g of dialysate.

1 g of the dialysate is dissolved in 100 mL of distilled water (1% solution) and 3% cetylpyridinium chloride (hereinafter referred to as C
PC) 30 mL of aqueous solution was added. After standing at 37 ° C. overnight, the precipitate (acid polysaccharide-CPC complex) was collected by centrifugation.

To the precipitate was added 350 mL of 4M NaCl, and the mixture was stirred at 37 ° C. overnight to dissociate the acidic polysaccharide and CPC. Thereafter, three times the amount of ethanol was added to precipitate the polysaccharide, and the precipitate was recovered by centrifugation. After repeating the above operation three times in total, the precipitate was washed with 400 mL of ethanol to completely remove the CPC.

The obtained precipitate was redissolved in 2 L of distilled water and filtered, and then distilled water was added to make a total volume of 6 L, and desalted using a hollow fiber. The solution after desalting was freeze-dried.

The lyophilized product was redissolved in 150 mL of distilled water, and 200 mL of a 2% CaCl ₂ aqueous solution was added. After thorough stirring, alginic acid was removed as a precipitate by centrifugation. The obtained supernatant was dialyzed against distilled water and freeze-dried to obtain 0.5 g of a fucoidan fraction.

[Test Example 1] (Test for promoting hyaluronic acid synthesis) Test Example 1: Test for promoting hyaluronic acid synthesis on rat keratinocytes Keratinocytes were separated from the skin of neonatal (3 day old) rats by trypsin treatment and cultured in a growth medium. After doing
The cells were cultured in a differentiation medium for 2 days.

Each of the fucoidans and other seaweed polysaccharides obtained in the above Preparation Examples was added to the cells at a concentration of 500 μg / mL for 72 hours.
The concentration of the hyaluronic acid released into the medium after being allowed to act for a time was measured by a hyaluronic acid binding protein assay method. Table 1 shows the results of calculating the amount of hyaluronic acid in the medium when the control was set to 1.00. The amount of hyaluronic acid (hyaluronic acid synthesis promoting ability) in Table 1 below was determined by the following equation. Hyaluronic acid synthesis promoting ability (magnification) = A / B A: Hyaluronic acid concentration in medium when each test substance was added (ng / mL) B: Hyaluronic acid concentration in medium without addition (ng / mL)
mL)

[0045]

[Table 1]

As shown in Table 1, the fucoidans of the present invention, namely, Matsumo, Mozuku, Kajime, Eckl
onia maxima, Lessonia nigr
escens, giant kelp, hibamata, fuc
us vesiculosus, Ascophyllu
m nodosum, Durville antenna
Fucoidan extracted from each seaweed of ctica was found to promote hyaluronic acid synthesis. Among them, those with particularly strong effects were Ecklonia maxima,
Hibamata, Fucus vesiculosus, Du
It was fucoidan from rvilleantarctica.

On the other hand, even if the brown algae are the same, they are out of the scope of the present invention, that is, fucoidan obtained from the kelp makombu or the genus Hondawara, and other polysaccharides characteristic of marine algae. Carrageenan and sodium alginate did not show any effect of promoting hyaluronic acid synthesis.

Test Example 2 (Hyaluronidase Activity Inhibition Test) The hyaluronidase inhibitory activity of each seaweed fucoidan obtained in the above Preparation Example was measured by the following method.

Enzyme (type IV-S from B)
ovine testis, SIGMA) solution 1
A sample 2 of each seaweed fucoidan and other seaweed polysaccharide obtained in the above-mentioned production example was prepared in a volume of 00 μL (1,380 units / mL).
After adding 00 μL, the mixture was left at 37 ° C. for 20 minutes. next,
Enzyme activator (Compound 48/80, SIG
MA) (0.1 mg / mL), and left at 37 ° C. for 20 minutes. Then, potassium hyaluronate (from a rooster comb,
500 μL of a solution (0.4 mg / mL, manufactured by Wako Pure Chemical Industries, Ltd.) was added and left at 37 ° C. for 40 minutes.

Then, a 0.4N sodium hydroxide solution 2
After adding 00 μL to stop the reaction, Morgan-
A modified version of the Elson method (J. Bio. Chem., 21
7, 959 (1955)) and the amount of N-acetylhexosamine produced was determined from the absorbance OD _{585 nm} .

A 0.1 mM acetate buffer (pH 3.5) was used for the enzymatic reaction, and the hyaluronidase inhibitory activity was calculated by the inhibition rate determined by the following equation.

[0052]

(Equation 1)

Table 2 shows the results of calculating the 50% inhibitory concentration (IC ₅₀ ) from the inhibition rates at various sample concentrations for each seaweed fucoidan obtained in the above Production Examples. The lower the value, the higher the inhibition of hyaluronidase activity.

[0054]

[Table 2]

As shown in Table 2, the fucoidans of the present invention, namely, Matsumo, Mozuku, Kajime, Eckl
onia maxima, Lessonia nigr
escens, giant kelp, hibamata, fuc
us vesiculosus, Ascophyllu
m nodosum, Durville antenna
Fucoidan extracted from each seaweed of ctica was found to strongly inhibit hyaluronidase activity. Among them, those with particularly strong effects were Kajime, Ecklonia
maxima, Lessonia nigresce
ns, Fucus vesiculosus, Durv
It was fucoidan derived from illea antarctica.

On the other hand, even if the brown algae are the same, they are out of the scope of the present invention, that is, fucoidan obtained from the kelp makombu or the genus Hondawara, and other polysaccharides characteristic of marine algae. The inhibitory activities of carrageenan and sodium alginate were low.

Test Example 3 (Histamine Release Inhibition Test) The histamine release inhibitory effect of each seaweed fucoidan obtained in the above Production Example was performed by the following method. A test substance such as fucoidan of each seaweed obtained in the above production example was used in Tyrod
10 μL of sample solution dissolved in solution e and adjusted to 1 mg / mL
Was mixed with 10 μL of rat peritoneal cell suspension, 37 ° C., 10
After incubating for 5 minutes, 5 μg / mL Compo
und 48/80 solution was added, and 37 ° C., 10
Allowed to act for minutes. The mixture was cooled on ice to stop the reaction, and after centrifugation, the supernatant was taken and an equal volume of 0.1 M hydrochloric acid was added. This solution was subjected to an on-column derivatization method (J. Chromato
gr. , Vol. 595, p163, 1992), and the peak area of free histamine was measured. The inhibition rates shown in Table 3 were calculated from the histamine peak area using the following formula. Here, the control area in the formula is a peak area of free histamine obtained using a Tyrode solution to which no test substance is added.

[0058]

(Equation 2)

[0059]

[Table 3]

As shown in Table 3, the fucoidans of the present invention, namely, Matsumo, Mozuku, Kajime, Eckl
onia maxima, Lessonia nigr
escens, giant kelp, hibamata, fuc
us vesiculosus, Ascophyllu
m nodosum, Durville antenna
Fucoidan extracted from each seaweed of ctica was found to have a strong histamine release inhibitory effect. Among them, the ones with particularly strong effects were swordfish and Eckloniamaxim.
a, Lessonia nigrescens, Fuc
us vesiculosus, Durvillea
Antarctica-derived fucoidan.

On the other hand, even the same brown algae, which are outside the scope of the present invention, ie, seaweeds such as Macomb of the genus Kombu, fucoidan obtained from Hondawara of the genus Hondawara, and other polysaccharides characteristic of seaweeds Carrageenan and sodium alginate did not show a strong inhibitory effect. When the above product was used in humans and evaluated, a very good effect was obtained.

Examples will be described below. In the following examples,% is% by weight. In addition, the total of the compounding amounts of the respective examples is 100.0%.

[0063]

[Table 4]

[0064]

[Table 5]

[0065]

[Table 6]

[0066]

[Table 7]

[0067]

[Table 8]

[0068]

[Table 9]

[0069]

[Table 10]

[0070]

[Table 11]

[0071]

[Table 12]

[0072]

[Table 13]

[0073]

[Table 14]

[0074]

[Table 15]

[0075]

[Table 16]

[0076]

[Table 17]

[0077]

[Table 18]

[0078]

[Table 19]

[0079]

[Table 20]

[0080]

[Table 21]

[0081]

[Table 22]

[0082]

[Table 23]

[0083]

[Table 24]

[0084]

[Table 25]

[0085]

EFFECT OF THE INVENTION The skin activator of the present invention has excellent hyaluronic acid synthesizing action and hyaluronidase inhibitory action, and an allergy inhibitor has an excellent histamine release inhibitory action.

──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. ⁶ Identification code FI A61K 31/725 ABF A61K 31/725 ABF C08B 37/00 C08B 37/00 Q

Claims (2)

[Claims] 1. A brown algae of the genus Matsumo, Mozuku, Swordfish, Lessonia, Macrocystis, Hibamata,
A skin activator containing, as an active ingredient, fucoidan extracted from one or two or more seaweeds belonging to the genera Ascophyllum and Darbilia. 2. Brown algae such as genus Matsumo, Mozuku, Laceae, Lessonia, Macrocystis, Hibamata,
An allergy suppressant containing as an active ingredient fucoidan extracted from one or more of the seaweeds belonging to the genera Ascophyllum and Darbilia.